If you are lucky enough to have $1,000 burning a hole in your pocket, then it could pay to put it to work in the share market.
But which ASX growth shares could be worth considering for these funds? Let's take a look at three that analysts rate as buys. They are as follows:
HMC Capital Ltd (ASX: HMC)
HMC Capital could be an ASX growth share to buy according to Goldman Sachs. It is a diversified alternative asset manager.
Goldman likes HMC Capital due to its growth strategy and the recent diversification away from traditional real estate. It highlights that it is "Buy rated given HMC's FUM growth strategy and diversification away from classic Real Estate and into Digital Infrastructure (including DigiCo) among various other strategies including Energy Transition and Private markets."
Goldman Sachs currently has a buy rating and $10.90 price target on HMC Capital's shares.
NextDC Ltd (ASX: NXT)
Another ASX growth share that Goldman Sachs is bullish on is NextDC. It could be a good option for your $1,000 if you want exposure to the AI boom without picking chip stocks or software companies.
That's because NextDC is Australia's leading data centre operator, providing essential infrastructure in the digital economy. With more businesses shifting to cloud and the explosion of AI workloads, the demand for power-hungry, high-performance data centres is soaring. This is music to the ears of NextDC and should be supportive of strong earnings growth long into the future.
Goldman Sachs expects this to be the case and has put a buy rating and $14.70 price target on its shares.
Telix Pharmaceuticals Ltd (ASX: TLX)
A final ASX growth share to consider for a $1,000 investment is Telix Pharmaceuticals.
It is quickly becoming a global leader in radiopharmaceuticals. These are targeted cancer therapies and imaging agents that deliver precision treatment with minimal side effects. Its flagship product Illuccix is already generating strong revenue, and several more therapies are on track for commercialisation in the near future.
Bell Potter is a big fan of the company. And while a recent FDA blow has put pressure on its shares, the broker thinks investors should be buying the dip. It notes that "this set back in registration in the US is of no help to clinicians or patients, nevertheless, we have seen similar outcomes on multiple occasions where the FDA does not fall into line with other regulators. Fortunately there is a path forward."
The broker recently put a buy rating and $34.00 price target on the company's shares.
